

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

Statistical parameters

When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).

n/a Confirmed

- ☐ ☒ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- ☐ ☒ An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- ☐ ☒ The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- ☐ ☒ A description of all covariates tested
- ☐ ☒ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- ☐ ☒ A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- ☐ ☒ For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- ☒ ☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- ☒ ☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- ☒ ☐ Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated
- ☐ ☒ Clearly defined error bars
State explicitly what error bars represent (e.g. SD, SE, CI)

Our web collection on [statistics for biologists](#) may be useful.

Software and code

Policy information about [availability of computer code](#)

Data collection

Zen software, CytExpert software, Excel

Data analysis

All statistical analyses were performed on Graphpad Prism (version 7). All flowcytometry data were analyzed on FlowJo software package (version 10.0.7; TreeStar, USA, 2014). Living image software (Perkin Elmer) was used to analyse bioluminescent and fluorescent images.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

A list of figures that have associated raw data.

Field-specific reporting

Please select the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/authors/policies/ReportingSummary-flat.pdf](https://www.nature.com/authors/policies/ReportingSummary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	The sample size were determined by G-power analysis software correspondingly.
Data exclusions	No data were excluded.
Replication	Experiments were repeated and experimental findings were reproducible.
Randomization	Mice were allocated randomly to each treatment group.
Blinding	No formal blinding was used. Bioluminescence imaging were conducted by an independent operator, who was unaware of the treatment conditions.

Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	Briefly describe the study type including whether data are quantitative, qualitative, or mixed-methods (e.g. qualitative cross-sectional, quantitative experimental, mixed-methods case study).
Research sample	State the research sample (e.g. Harvard university undergraduates, villagers in rural India) and provide relevant demographic information (e.g. age, sex) and indicate whether the sample is representative. Provide a rationale for the study sample chosen. For studies involving existing datasets, please describe the dataset and source.
Sampling strategy	Describe the sampling procedure (e.g. random, snowball, stratified, convenience). Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient. For qualitative data, please indicate whether data saturation was considered, and what criteria were used to decide that no further sampling was needed.
Data collection	Provide details about the data collection procedure, including the instruments or devices used to record the data (e.g. pen and paper, computer, eye tracker, video or audio equipment) whether anyone was present besides the participant(s) and the researcher, and whether the researcher was blind to experimental condition and/or the study hypothesis during data collection.
Timing	Indicate the start and stop dates of data collection. If there is a gap between collection periods, state the dates for each sample cohort.
Data exclusions	If no data were excluded from the analyses, state so OR if data were excluded, provide the exact number of exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.
Non-participation	State how many participants dropped out/declined participation and the reason(s) given OR provide response rate OR state that no participants dropped out/declined participation.
Randomization	If participants were not allocated into experimental groups, state so OR describe how participants were allocated to groups, and if allocation was not random, describe how covariates were controlled.

Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	Briefly describe the study. For quantitative data include treatment factors and interactions, design structure (e.g. factorial, nested, hierarchical), nature and number of experimental units and replicates.
Research sample	Describe the research sample (e.g. a group of tagged <i>Passer domesticus</i> , all <i>Stenocereus thurberi</i> within Organ Pipe Cactus National Monument), and provide a rationale for the sample choice. When relevant, describe the organism taxa, source, sex, age range and

any manipulations. State what population the sample is meant to represent when applicable. For studies involving existing datasets, describe the data and its source.

Sampling strategy

Note the sampling procedure. Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.

Data collection

Describe the data collection procedure, including who recorded the data and how.

Timing and spatial scale

Indicate the start and stop dates of data collection, noting the frequency and periodicity of sampling and providing a rationale for these choices. If there is a gap between collection periods, state the dates for each sample cohort. Specify the spatial scale from which the data are taken

Data exclusions

If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.

Reproducibility

Describe the measures taken to verify the reproducibility of experimental findings. For each experiment, note whether any attempts to repeat the experiment failed OR state that all attempts to repeat the experiment were successful.

Randomization

Describe how samples/organisms/participants were allocated into groups. If allocation was not random, describe how covariates were controlled. If this is not relevant to your study, explain why.

Blinding

Describe the extent of blinding used during data acquisition and analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study.

Did the study involve field work? ☐ Yes ☐ No

Field work, collection and transport

Field conditions

Describe the study conditions for field work, providing relevant parameters (e.g. temperature, rainfall).

Location

State the location of the sampling or experiment, providing relevant parameters (e.g. latitude and longitude, elevation, water depth).

Access and import/export

Describe the efforts you have made to access habitats and to collect and import/export your samples in a responsible manner and in compliance with local, national and international laws, noting any permits that were obtained (give the name of the issuing authority, the date of issue, and any identifying information).

Disturbance

Describe any disturbance caused by the study and how it was minimized.

Reporting for specific materials, systems and methods

Materials & experimental systems

- | | |
|-------------------------------------|---|
| n/a | Involved in the study |
| ☒ | ☐ Unique biological materials |
| ☐ | ☒ Antibodies |
| ☐ | ☒ Eukaryotic cell lines |
| ☒ | ☐ Palaeontology |
| ☐ | ☒ Animals and other organisms |
| ☒ | ☐ Human research participants |

Methods

- | | |
|-------------------------------------|--|
| n/a | Involved in the study |
| ☒ | ☐ ChIP-seq |
| ☐ | ☒ Flow cytometry |
| ☒ | ☐ MRI-based neuroimaging |

Unique biological materials

Policy information about [availability of materials](#)

Obtaining unique materials

Describe any restrictions on the availability of unique materials OR confirm that all unique materials used are readily available from the authors or from standard commercial sources (and specify these sources).

Antibodies

Antibodies used

The following primary antibodies were used for blocking. They are listed as antigen first, followed by supplier, catalog number and clone/lot number as applicable. All the antibodies were diluted and used following the supplier protocol.
 1) Anti-mouse CD47, Biolegend Inc, cat. no. 127518, Clone: miap301;
 2) Anti-mouse PD1, Biolegend Inc, cat. no. 135233, Clone: 29F.1A12;

The following primary antibodies were used for western blotting. They are listed as antigen first, followed by supplier, catalog number and clone/lot number as applicable.

- 1) Anti HIF1- α (28b), Santa Cruz, cat. no. sc-13515;
- 2) Anti-beta actin, Abcam, cat. no. ab8226;
- 3) Goat anti-mouse antibody, Novus Biologicals, cat. no. NBP1-75151;

The following primary antibodies were used for immunofluorescence. They are listed as antigen first, followed by supplier, catalog number and clone/lot number as applicable.

- 1) Rhodamine (TRITC)-conjugated donkey anti-rat IgG antibody, Jackson Immuno Research Labs, cat. no. NC9656482;
- 2) Anti-mouse CD4, Abcam, cat. no. ab183685;
- 3) Anti-mouse CD8, Abcam, cat. no. ab22378;
- 4) Anti-mouse F4/80, Abcam, cat. no. ab100790;
- 5) Goat anti-rat IgG, H + L, Thermo Fisher Scientific, cat. no. A21247;
- 6) Goat anti-rabbit IgG, H + L, Thermo Fisher Scientific, cat. no. A11034;

The following primary antibodies were used for flow cytometry. They are listed as antigen first, followed by supplier, catalog number and clone/lot number as applicable.

- 1) Anti-mouse CD45, Biolegend, cat. no. 103108, Clone: 30-F11;
- 2) Anti-mouse CD11b, Biolegend, cat. no. 101208, Clone: M1/70;
- 3) Anti-mouse CD206, Biolegend, cat. no. 141716, Clone: C068C2;
- 4) Anti-mouse F4/80, Biolegend, cat. no. 123116, Clone: BM8;
- 5) Anti-mouse CD80, Biolegend, cat. no. 104722, Clone: 16-10A1;
- 6) Anti-mouse Gr-1, Biolegend, cat. no. 108412, Clone: RB6-8C5;
- 7) Anti-mouse CD3, Biolegend, cat. no. 100204, Clone: 17A2;
- 8) Anti-mouse CD4, Biolegend, cat. no. 100412, Clone: GK1.5;
- 9) Anti-mouse CD8, Biolegend, cat. no. 140408, Clone: 53-5.8;
- 10) Anti-mouse Foxp3, Biolegend, cat. no. 126404, Clone: MF-14;
- 11) Anti-mouse CD11c, Biolegend, cat. no. 117310, Clone: N418;
- 12) Anti-mouse CD86, Biolegend, cat. no. 105008, Clone: GL-1;
- 13) Anti-mouse CD103, Biolegend, cat. no. 121406, Clone: 2E7;
- 14) Anti-mouse Ly6C, Biolegend, cat. no. 128016, Clone: HK1.4;
- 15) Anti-mouse Ly6G, Biolegend, cat. no. 127608, Clone: 1A8;

The following primary antibodies were used for ELISA. They are listed as antigen first, followed by supplier, catalog number and clone/lot number as applicable.

- 1) Anti-rat IgG, eBioscience, cat. no. 88-50490-22;
- 2) Anti-mouse IL10, Invitrogen, cat. no. BMS215-2;
- 3) Anti-mouse IL12p70, Invitrogen, cat. no. BMS6004TEN;
- 4) Anti-mouse IL 6, Invitrogen, cat. no. BMS603-2;
- 5) Anti-mouse TNF- α , Invitrogen, cat. no. BMS607-3;
- 6) Anti-mouse IFN gamma, Invitrogen, cat. no. BMS606INST;

Validation

All antibodies were verified by the supplier and each lot has been quality tested.

Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)

The murine melanoma cell line B16F10 was purchased from UNC tissue culture facility. B16F10-luc cells were obtained from Dr. Leaf Huang at UNC.

Authentication

The cells lines were authenticated by IDEXX BioResearch and the UNC-tissue culture facility for pathogen testing.

Mycoplasma contamination

All cell lines were tested for mycoplasma contamination. No mycoplasma contamination was found.

Commonly misidentified lines (See [ICLAC](#) register)

No commonly misidentified cell lines were used.

Palaeontology

Specimen provenance

Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information).

Specimen deposition

Indicate where the specimens have been deposited to permit free access by other researchers.

Dating methods

If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.

☐ Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

Laboratory animals

Female C57BL/6 mice (6–10 weeks) were purchased from Jackson Lab.

Wild animals

The study did not involve wild animals.

Field-collected samples

The study did not involve samples collected from field.

Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics

Describe the covariate-relevant population characteristics of the human research participants (e.g. age, gender, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."

Recruitment

Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.

ChIP-seq

Data deposition

☐ Confirm that both raw and final processed data have been deposited in a public database such as [GEO](#).

☐ Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links

May remain private before publication.

For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, provide a link to the deposited data.

Files in database submission

Provide a list of all files available in the database submission.

Genome browser session

(e.g. [UCSC](#))

Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review. Write "no longer applicable" for "Final submission" documents.

Methodology

Replicates

Describe the experimental replicates, specifying number, type and replicate agreement.

Sequencing depth

Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired- or single-end.

Antibodies

Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot number.

Peak calling parameters

Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files used.

Data quality

Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold enrichment.

Software

Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community repository, provide accession details.

Flow Cytometry

Plots

Confirm that:

- ☒ The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- ☒ The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- ☒ All plots are contour plots with outliers or pseudocolor plots.
- ☒ A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

- Sample preparation For tissue sample, the tissue was first mechanically disrupted from mice and divided into small pieces and homogenized in cold staining buffer to form single cell suspensions in the presence of digestive enzyme.
- Instrument CytoFLEX flow cytometer (Beckman)
- Software FlowJo software package (version 10.0.7; TreeStar, USA, 2014)
- Cell population abundance No sorting was performed.
- Gating strategy Generally, cells was first gated on FSC/SSC. Singlet cells were usually gated using FSC-H and FSC-A. Surface antigen gating was performed on the live cell population.
- ☒ Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

Magnetic resonance imaging

Experimental design

- Design type Indicate task or resting state; event-related or block design.
- Design specifications Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.
- Behavioral performance measures State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects).

Acquisition

- Imaging type(s) Specify: functional, structural, diffusion, perfusion.
- Field strength Specify in Tesla
- Sequence & imaging parameters Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, slice thickness, orientation and TE/TR/flip angle.
- Area of acquisition State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determined.
- Diffusion MRI ☐ Used ☐ Not used

Preprocessing

- Preprocessing software Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, segmentation, smoothing kernel size, etc.).
- Normalization If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types used for transformation OR indicate that data were not normalized and explain rationale for lack of normalization.
- Normalization template Describe the template used for normalization/transformation, specifying subject space or group standardized space (e.g. original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.
- Noise and artifact removal Describe your procedure(s) for artifact and structured noise removal, specifying motion parameters, tissue signals and physiological signals (heart rate, respiration).
- Volume censoring Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.

Statistical modeling & inference

Model type and settings

Specify type (mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first and second levels (e.g. fixed, random or mixed effects; drift or auto-correlation).

Effect(s) tested

Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether ANOVA or factorial designs were used.

Specify type of analysis: ☐ Whole brain ☐ ROI-based ☐ BothStatistic type for inference
(See [Eklund et al. 2016](#))

Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.

Correction

Describe the type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte Carlo).

Models & analysis

n/a | Involved in the study

- ☐ ☐ Functional and/or effective connectivity
- ☐ ☐ Graph analysis
- ☐ ☐ Multivariate modeling or predictive analysis

Functional and/or effective connectivity

Report the measures of dependence used and the model details (e.g. Pearson correlation, partial correlation, mutual information).

Graph analysis

Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency, etc.).

Multivariate modeling and predictive analysis

Specify independent variables, features extraction and dimension reduction, model, training and evaluation metrics.